GSK, Pfizer RSV vaccine sales fall in US
GSK has agreed to pay $2.2 billion to settle most of the pending lawsuits that claimed a discontinued version of the Zantac ...
RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age ...
The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.
Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034 ...
Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...
In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...
U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback